ILF3 promotes gastric cancer proliferation and may be used as a prognostic marker

Liu,Yü; Li,Yong; Zhao,Yijie; Liu,Yang; Fan,Liqiao; Jia,Nan; Zhao,Qun

doi:10.3892/mmr.2019.10229

ILF3 promotes gastric cancer proliferation and may be used as a prognostic marker

Authors:
- Yü Liu
- Yong Li
- Yijie Zhao
- Yang Liu
- Liqiao Fan
- Nan Jia
- Qun Zhao
View Affiliations

Affiliations: Department of General Surgery, Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, Hebei 050011, P.R. China
Published online on: May 9, 2019 https://doi.org/10.3892/mmr.2019.10229
Pages: 125-134
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Interleukin enhancer‑binding factor 3 (ILF3) may function as a transcriptional coactivator and has been reported to be involved in tumor proliferation and metastasis; however, its role and clinical value in gastric cancer (GC) remains unclear. To understand the value of ILF3 in GC, a total of 80 matched samples selected from GC tissues and the adjacent mucosa were used to evaluate the expression of ILF3 and its association with clinical characteristics. Furthermore, its biological functions and mechanisms were investigated using SGC‑7901 and BGC823 cell lines. Immunohistochemistry demonstrated that the positive expression rates of ILF3 in GC tissue were higher compared with those in adjacent mucosa (P<0.05). Significantly overexpressed ILF3 was detected in BGC823 and SGC7901 cells, and the MTT results demonstrated decreased cell activity after ILF3 expression was inhibited. The proportions of cells in the G0/G1 phase increased, while the number of cells in the G2/M phase decreased, and the expression of the genes associated with proliferation varied following inhibition of ILF3 (P<0.05). Positive expression of ILF3 was associated with a poor prognosis for patients with GC, and was an independent risk factor for GC (P<0.05). In conclusion, ILF3 is involved in the deterioration of GC by promoting proliferation of GC cells, and ILF3 protein detection may assist in the prediction of the prognosis of patients with GC.

View Figures

View References

1	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
2	Wang W, Zheng C, Fang C, Li P, Xie J, Lin J, Zhan Y, Li W, Chen Y, Sun X, et al: Time trends of clinicopathologic features and surgical treatment for gastric cancer: Results from 2 high-volume institutions in southern China. Surgery. 158:1590–1597. 2015. View Article : Google Scholar : PubMed/NCBI
3	Li ZX and Kaminishi M: A comparison of gastric cancer between Japan and China. Gastric Cancer. 12:52–53. 2009. View Article : Google Scholar : PubMed/NCBI
4	Bolke E, Peiper M and Budach W: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 358:19652008. View Article : Google Scholar : PubMed/NCBI
5	Wang YJ, Liu JZ, Lv P, Dang Y, Gao JY and Wang Y: Long non-coding RNA CCAT2 promotes gastric cancer proliferation and invasion by regulating the E-cadherin and LATS2. Am J Cancer Res. 6:2651–2660. 2016.PubMed/NCBI
6	Nakadai T, Fukuda A, Shimada M, Nishimura K and Hisatake K: The RNA binding complexes NF45-NF90 and NF45-NF110 associate dynamically with the c-fos gene and function as transcriptional coactivators. J Biol Chem. 290:26832–26845. 2015. View Article : Google Scholar : PubMed/NCBI
7	Agnoletto C, Brunelli L, Melloni E, Pastorelli R, Casciano F, Rimondi E, Rigolin GM, Cuneo A, Secchiero P and Zauli G: The anti-leukemic activity of sodium dichloroacetate in p53mutated/null cells is mediated by a p53-independent ILF3/p21 pathway. Oncotarget. 6:2385–2396. 2015. View Article : Google Scholar : PubMed/NCBI
8	Jiang W, Huang H, Ding L, Zhu P, Saiyin H, Ji G, Zuo J, Han D, Pan Y, Ding D, et al: Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability. Oncogene. 34:4460–4470. 2015. View Article : Google Scholar : PubMed/NCBI
9	Hu Q, Lu YY, Noh H, Hong S, Dong Z, Ding HF, Su SB and Huang S: Interleukin enhancer-binding factor 3 promotes breast tumor progression by regulating sustained urokinase-type plasminogen activator expression. Oncogene. 32:3933–3943. 2013. View Article : Google Scholar : PubMed/NCBI
10	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
11	Qiu M, Zhou Y, Jin Y, Wei XL, Wang DS, Ren C, Bai L, Yang DJ and Xu RH: Prognostic effect of high pretreatment neutrophil to lymphocyte ratio on survival of patients with gastric adenocarcinoma in China. Int J Biol Markers. 30:e96–e103. 2015. View Article : Google Scholar : PubMed/NCBI
12	Li P, He HQ, Zhu CM, Ling YH, Hu WM, Zhang XK, Luo RZ, Yun JP, Xie D, Li YF and Cai MY: The prognostic significance of lymphovascular invasion in patients with resectable gastric cancer: A large retrospective study from Southern China. BMC Cancer. 15:3702015. View Article : Google Scholar : PubMed/NCBI
13	Liu Q, Bi JJ, Tian YT, Feng Q, Zheng ZX and Wang Z: Outcome after simultaneous resection of gastric primary tumour and synchronous liver metastases: survival analysis of a single-center experience in China. Asian Pac J Cancer Prev. 16:1665–1669. 2015. View Article : Google Scholar : PubMed/NCBI
14	Zhang J, Sun Z, Han Y, Yao R, Yue L, Xu Y and Zhang J: Rnf2 knockdown reduces cell viability and promotes cell cycle arrest in gastric cancer cells. Oncol Lett. 13:3817–3822. 2017. View Article : Google Scholar : PubMed/NCBI
15	Wei S, Li Q, Li Z, Wang L, Zhang L and Xu Z: Correction: miR-424-5p promotes proliferation of gastric cancer by targeting Smad3 through TGF-β signaling pathway. Oncotarget. 8:340182017. View Article : Google Scholar : PubMed/NCBI
16	Jia S, Qu T, Wang X, Feng M, Yang Y, Feng X, Ma R, Li W, Hu Y, Feng Y, et al: KIAA1199 promotes migration and invasion by Wnt/β-catenin pathway and MMPs mediated EMT progression and serves as a poor prognosis marker in gastric cancer. PLoS One. 12:e01750582017. View Article : Google Scholar : PubMed/NCBI
17	Li Y, Ye J, Chen Z, Wen J, Li F, Su P, Lin Y, Hu B, Wu D, Ning L, et al: Annonaceous acetogenins mediated up-regulation of Notch2 exerts growth inhibition in human gastric cancer cells in vitro. Oncotarget. 8:21140–21152. 2017.PubMed/NCBI
18	Castella S, Bernard R, Corno M, Fradin A and Larcher JC: Ilf3 and NF90 functions in RNA biology. Wiley Interdiscip Rev RNA. 6:243–256. 2015. View Article : Google Scholar : PubMed/NCBI
19	Li T, Li X, Zhu W, Wang H, Mei L, Wu S, Lin X and Han X: NF90 is a novel influenza A virus NS1-interacting protein that antagonizes the inhibitory role of NS1 on PKR phosphorylation. FEBS Lett. 590:2797–2810. 2016. View Article : Google Scholar : PubMed/NCBI
20	Jayachandran U, Grey H and Cook AG: Nuclear factor 90 uses an ADAR2-like binding mode to recognize specific bases in dsRNA. Nucleic Acids Res. 44:1924–1936. 2016. View Article : Google Scholar : PubMed/NCBI
21	Wan C, Gong C, Ji L, Liu X, Wang Y, Wang L, Shao M, Yang L, Fan S, Xiao Y, et al: NF45 overexpression is associated with poor prognosis and enhanced cell proliferation of pancreatic ductal adenocarcinoma. Mol Cell Biochem. 410:25–35. 2015. View Article : Google Scholar : PubMed/NCBI
22	Masuda K, Kuwano Y, Nishida K, Rokutan K and Imoto I: NF90 in posttranscriptional gene regulation and microRNA biogenesis. Int J Mol Sci. 14:17111–17121. 2013. View Article : Google Scholar : PubMed/NCBI
23	Ovestad IT, Dalen I, Hansen E, Loge JL, Dybdahl BM, Dirdal MB, Moltu P and Berland JM: Clinical value of fully automated p16/Ki-67 dual staining in the triage of HPV-positive women in the Norwegian Cervical Cancer Screening Program. Cancer. 125:283–291. 2017.
24	Wang FL, Yang Y, Liu ZY, Qin Y and Jin T: Correlation between methylation of the p16 promoter and cervical cancer incidence. Eur Rev Med Pharmacol Sci. 21:2351–2356. 2017.PubMed/NCBI
25	Wang LL, Guo HH, Zhan Y, Feng CL, Huang S, Han YX, Zheng WS and Jiang JD: Specific up-regulation of p21 by a small active RNA sequence suppresses human colorectal cancer growth. Oncotarget. 8:25055–25065. 2017.PubMed/NCBI
26	Li LH, Wu GY, Lu YZ, Chen XH, Liu BY, Zheng MH and Cai JC: p21-activated protein kinase 1 induces the invasion of gastric cancer cells through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase-2. Oncol Rep. 38:193–200. 2017. View Article : Google Scholar : PubMed/NCBI
27	Cheng R, Liu YJ, Cui JW, Yang M, Liu XL, Li P, Wang Z, Zhu LZ, Lu SY, Zou L, et al: Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells. Oncotarget. 8:30252–30302. 2017.PubMed/NCBI
28	Kim Y, Kim H, Park D, Lee H, Lee YS, Choe J, Kim YM, Jeon D and Jeoung D: The pentapeptide Gly-Thr-Gly-Lys-Thr confers sensitivity to anti-cancer drugs by inhibition of CAGE binding to GSK3β and decreasing the expression of cyclinD1. Oncotarget. 8:13632–13651. 2017.PubMed/NCBI